BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 37302631)

  • 1. CircEGFR reduces the sensitivity of pirarubicin and regulates the malignant progression of triple-negative breast cancer via the miR-1299/EGFR axis.
    Ma J; Chen C; Fan Z; Zhang Y; Ji J; Wei D; Zhang F; Sun B; Huang P; Ren L
    Int J Biol Macromol; 2023 Jul; 244():125295. PubMed ID: 37302631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel exosomal circEGFR facilitates triple negative breast cancer autophagy via promoting TFEB nuclear trafficking and modulating miR-224-5p/ATG13/ULK1 feedback loop.
    Song H; Zhao Z; Ma L; Zhao W; Hu Y; Song Y
    Oncogene; 2024 Mar; 43(11):821-836. PubMed ID: 38280941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hsa_circRNA_102229 facilitates the progression of triple-negative breast cancer via regulating the miR-152-3p/PFTK1 pathway.
    Du C; Zhang J; Zhang L; Zhang Y; Wang Y; Li J
    J Gene Med; 2021 Sep; 23(9):e3365. PubMed ID: 34031947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hsa_circ_0000199 facilitates chemo-tolerance of triple-negative breast cancer by interfering with miR-206/613-led PI3K/Akt/mTOR signaling.
    Li H; Xu W; Xia Z; Liu W; Pan G; Ding J; Li J; Wang J; Xie X; Jiang D
    Aging (Albany NY); 2021 Jan; 13(3):4522-4551. PubMed ID: 33495420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circ_0000520 contributes to triple-negative breast cancer progression through mediating the miR-1296/ZFX axis.
    Zhou Y; Ma G; Peng S; Tuo M; Li Y; Qin X; Yu Q; Kuang S; Cheng H; Li J
    Thorac Cancer; 2021 Sep; 12(18):2427-2438. PubMed ID: 34324278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Down-regulating GRP78 reverses pirarubicin resistance of triple negative breast cancer by miR-495-3p mimics and involves the p-AKT/mTOR pathway.
    Liu M; Yang J; Lv W; Wang S; Du T; Zhang K; Wu Y; Feng X
    Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34935899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CircWHSC1 regulates malignancy and glycolysis by the miR-212-5p/AKT3 pathway in triple-negative breast cancer.
    Ding L; Xie Z
    Exp Mol Pathol; 2021 Dec; 123():104704. PubMed ID: 34624276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circular RNA circEGFR regulates tumor progression via the miR-106a-5p/DDX5 axis in colorectal cancer.
    Fu P; Lin L; Zhou H; Zhao S; Jie Z
    Braz J Med Biol Res; 2021; 54(8):e10940. PubMed ID: 34320120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CircDUSP1 regulates tumor growth, metastasis, and paclitaxel sensitivity in triple-negative breast cancer by targeting miR-761/DACT2 signaling axis.
    Huang S; Xie J; Lei S; Fan P; Zhang C; Huang Z
    Mol Carcinog; 2023 Apr; 62(4):450-463. PubMed ID: 36562476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circ_0062558 promotes growth, migration, and glutamine metabolism in triple-negative breast cancer by targeting the miR-876-3p/SLC1A5 axis.
    Yuan M; Zhang J; He Y; Yi G; Rong L; Zheng L; Zhan T; Zhou C
    Arch Gynecol Obstet; 2022 Nov; 306(5):1643-1655. PubMed ID: 35284960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circ_0004676 exacerbates triple-negative breast cancer progression through regulation of the miR-377-3p/E2F6/PNO1 axis.
    Shao G; Fan X; Zhang P; Liu X; Huang L; Ji S
    Cell Biol Toxicol; 2023 Oct; 39(5):2183-2205. PubMed ID: 35870038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circular RNA circ-ERBB2 Elevates the Warburg Effect and Facilitates Triple-Negative Breast Cancer Growth by the MicroRNA 136-5p/Pyruvate Dehydrogenase Kinase 4 Axis.
    Huang Y; Zheng S; Lin Y; Ke L
    Mol Cell Biol; 2021 Sep; 41(10):e0060920. PubMed ID: 34370552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circular RNA circPTK2 modulates migration and invasion via miR-136/NFIB signaling on triple-negative breast cancer cells in vitro.
    Wang M; Chen D; Zhang H; Luo C
    Inflamm Res; 2022 Apr; 71(4):409-421. PubMed ID: 35234989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Circ_0000977-Mediated Regulatory Network in Breast Cancer: A Potential Discriminative Biomarker for Triple-Negative Tumors.
    Darbeheshti F; Mansoori Y; Azizi-Tabesh G; Zolfaghari F; Kadkhoda S; Rasti A; Rezaei N; Shakoori A
    Biochem Genet; 2023 Aug; 61(4):1487-1508. PubMed ID: 36645554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circular RNA circ-ZEB1 acts as an oncogene in triple negative breast cancer via sponging miR-448.
    Pei X; Zhang Y; Wang X; Xue B; Sun M; Li H
    Int J Biochem Cell Biol; 2020 Sep; 126():105798. PubMed ID: 32629026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. circRAD18 sponges miR-208a/3164 to promote triple-negative breast cancer progression through regulating IGF1 and FGF2 expression.
    Zou Y; Zheng S; Xiao W; Xie X; Yang A; Gao G; Xiong Z; Xue Z; Tang H; Xie X
    Carcinogenesis; 2019 Dec; 40(12):1469-1479. PubMed ID: 31001629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-92b inhibited cells EMT by targeting Gabra3 and predicted prognosis of triple negative breast cancer patients.
    Li YY; Zheng XH; Deng AP; Wang Y; Liu J; Zhou Q; Cheng GY; Jiang Q
    Eur Rev Med Pharmacol Sci; 2019 Dec; 23(23):10433-10442. PubMed ID: 31841197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circ-TRIO promotes TNBC progression by regulating the miR-432-5p/CCDC58 axis.
    Wang Z; Li Y; Yang J; Liang Y; Wang X; Zhang N; Kong X; Chen B; Wang L; Zhao W; Yang Q
    Cell Death Dis; 2022 Sep; 13(9):776. PubMed ID: 36075896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CircWAC induces chemotherapeutic resistance in triple-negative breast cancer by targeting miR-142, upregulating WWP1 and activating the PI3K/AKT pathway.
    Wang L; Zhou Y; Jiang L; Lu L; Dai T; Li A; Chen Y; Zhang L
    Mol Cancer; 2021 Mar; 20(1):43. PubMed ID: 33648498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The circRNA circAGFG1 acts as a sponge of miR-195-5p to promote triple-negative breast cancer progression through regulating CCNE1 expression.
    Yang R; Xing L; Zheng X; Sun Y; Wang X; Chen J
    Mol Cancer; 2019 Jan; 18(1):4. PubMed ID: 30621700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.